Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Has Average Price Target of $3.83

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) has earned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $3.83.

A number of research analysts have commented on NAUT shares. Weiss Ratings downgraded Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Leerink Partners initiated coverage on Nautilus Biotechnology in a research note on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price objective on the stock. Roth Capital started coverage on shares of Nautilus Biotechnology in a report on Tuesday. They set a “buy” rating and a $3.50 target price on the stock. Finally, Zacks Research raised shares of Nautilus Biotechnology to a “hold” rating in a report on Wednesday.

Institutional Investors Weigh In On Nautilus Biotechnology

A number of institutional investors have recently added to or reduced their stakes in the company. TD Waterhouse Canada Inc. grew its holdings in shares of Nautilus Biotechnology by 1,500.0% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after purchasing an additional 15,000 shares in the last quarter. CTC Alternative Strategies Ltd. bought a new position in Nautilus Biotechnology in the first quarter worth $48,000. Callan Family Office LLC acquired a new stake in Nautilus Biotechnology during the second quarter worth $49,000. Squarepoint Ops LLC acquired a new stake in Nautilus Biotechnology during the second quarter worth $63,000. Finally, AXQ Capital LP bought a new stake in Nautilus Biotechnology in the 2nd quarter valued at $64,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Price Performance

NASDAQ NAUT opened at $1.57 on Friday. The company has a market capitalization of $199.78 million, a price-to-earnings ratio of -3.49 and a beta of 0.73. Nautilus Biotechnology has a 12 month low of $0.82 and a 12 month high of $4.31. The company’s fifty day moving average price is $1.01 and its two-hundred day moving average price is $2.01.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its earnings results on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.10 million. As a group, analysts anticipate that Nautilus Biotechnology will post -0.52 EPS for the current year.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods.

The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine.

Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington.